BCL2 and cancer: The first, highly selective BCL2 inhibitor venetoclax (ABT-199) binds specifically to BCL2 and displaces BH3 domain-only proteins to trigger BAX/BAK-mediated mitochondria-induced apoptosis of cancer, including AML cells25,26.